Towards a pharmacologically guided individualization of imatinib and sunitnib therapy
Naar een individualisatie van imatinib en sunitinib therapie op geleide van farmacologische eigenschappen
The approval of imatinib mesylate (Gleeve) in 2001 has added a new class of drugs to the systemic treatment of cancer: that of the tyrosine kinase inhibitors (TKIs). Imatinib inhibits autophosphorylation of specific proteins involved in oncogenesis such as the BCR-ABL fusion protein (expressed in Philadelphia chromosome positive chronic myeloid leukemia), c-KIT (expressed in gastrointestinal stromal tumors; GIST) and the plateletderived growth factor receptor (PDGFR; i.e. expressed in GIST and several sarcomas). After a decade of therapeutic use, imatinib has proven to be a highly effective targeted agent with a median overall survival in advanced GIST patients close to 5 years.
|cancer therapy, imatinib and sunitinib drugs, leukemia, oncology|
|J. Verweij (Jaap)|
|Erasmus University Rotterdam|
|Organisation||Erasmus MC: University Medical Center Rotterdam|
Eechoute, K. (2012, April 25). Towards a pharmacologically guided individualization of imatinib and sunitnib therapy . Erasmus University Rotterdam. Retrieved from http://hdl.handle.net/1765/38185